NCT07184086 - A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

October 12, 2027

Study Completion Date

October 12, 2027

Conditions

Obesity

Interventions

DRUG

CagriSema (Cagrilintide B + semaglutide I)

Cagrilintide and semaglutide will be administered subcutaneously.

BEHAVIORAL

Low Energy Diet

Participants will receive dietary intervention as per diet intervention manual.

Trial Locations (2)

RECRUITING

Advent Health-Res Inst, Orlando

RECRUITING

Pennington Biomed Res Ctr, Baton Rouge